Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway

References

• Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. 2006. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology 24: 4293–4300.
   PubMed Web of Science ®Google Scholar
• Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG. 2000. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Research 60:6597–6600.
   PubMed Web of Science ®Google Scholar
• Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. 2008. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 27:5315–5325.
   PubMed Web of Science ®Google Scholar
• Cabrera R, Nelson DR. 2010. Review article: The management of hepatocellular carcinoma. Alimentary Pharmacology & Theraputics 31:461–476.
   PubMed Web of Science ®Google Scholar
• Casarez EV, Dunlap-Brown ME, Conaway MR, Amorino GP. 2007. Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models. Cancer Research 67:8316–8324.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 10:25–34.
   PubMed Web of Science ®Google Scholar
• Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D. 2009. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clinical Cancer Research 15:3050–3057.
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P and Grant S. 2008. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112:2439–2449.
   Google Scholar
• Gailhouste L, Ezan F, Bessard A, Fremin C, Rageul J, Langouet S, Baffet G. 2010. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. International Journal of Cancer 126:1367–1377.
   PubMed Web of Science ®Google Scholar
• Girard N, Mornex F. 2011. Sorafenib and radiotherapy association for hepatocellular carcinoma. Cancer Radiotherapy 15:77–80.
   PubMed Web of Science ®Google Scholar
• Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K. 2007. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Research 67:1046–1053.
   PubMed Web of Science ®Google Scholar
• Hall EJ. 2006. Radiobiology for the radiologist. 6th ed. Philadelphia, PA, USA: Lippincott Williams and Wilkins.
   Google Scholar
• Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar SK, Klein P, Bansal N, Schmidt CM. 2010. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology 51:1218–1225.
   PubMed Web of Science ®Google Scholar
• Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, Muanza T. 2012. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anticancer Drugs 23:525–533.
   Google Scholar
• Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, Luu DA, Jong CT, Lam IW. 2011. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. Anticancer Agents in Medicinal Chemistry 11:560–575.
   PubMed Web of Science ®Google Scholar
• Huynh H, Soo KC, Chow PK, Tran E. 2007. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Molecular Cancer Therapeutics 6:138–146.
   PubMed Web of Science ®Google Scholar
• Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. 2006. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131:1208–1217.
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 66:11851–11858.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. 2008. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 359:378–390.
   Google Scholar
• Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. 2007. Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma. Clinical Genitourinary Cancer 5:291–294.
   PubMed Web of Science ®Google Scholar
• Marampon F, Gravina GL, Rocco AD, Bonfili P, Staso MD, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, Pestell RG, Tombolini V, Zani BM. 2011. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Molecular Cancer Therapy 10:159–168.
   PubMed Web of Science ®Google Scholar
• McKenna WG, Bernhard EJ, Markiewicz DA, Rudoltz MS, Maity A, Muschel RJ. 1996. Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: Influence of H-ras on the G2 delay. Oncogene 12:237–245.
   PubMed Web of Science ®Google Scholar
• Min L, He B, Hui L. 2011. Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in Cancer Biology 21:10–20.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. 2001. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 94: 153–156.
   PubMed Web of Science ®Google Scholar
• Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. 2003. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochemistry and Cell Biology 81: 123–129.
   PubMed Web of Science ®Google Scholar
• Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. 2007. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Research 67:9443–9454.
   PubMed Web of Science ®Google Scholar
• Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. 2009. Current management strategy of hepatocellular carcinoma. World Journal of Gastroenterology 15:3210–3216.
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of Biological Chemistry 273:5858–5868.
   PubMed Web of Science ®Google Scholar
• Rothkamm K, Krüger I, Thompson LH, Löbrich M. 2003. Pathways of DNA double-strand break repair during the mammalian cell cycle. Molecular and Cellular Biology 23:5706–5715.
   PubMed Web of Science ®Google Scholar
• Rothkamm K, Löbrich M. 2003. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proceedings of the National Academy of Sciences of the USA 100:5057–5062.
   Google Scholar
• Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM. 2009. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf> MEK> ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiotherapy and Oncology 93:639–644.
   PubMed Web of Science ®Google Scholar
• Sherman M. 2010. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Seminars in Liver Disease 30:303–316.
   Web of Science ®Google Scholar
• Sklar MD. 1988. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645–647.
   PubMed Web of Science ®Google Scholar
• Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM, Wilson GD. 2010. Sorafenib and radiation: A promising combination in colorectal cancer. International Journal of Radiation Oncology Biology Physics 78:213–220.
   PubMed Web of Science ®Google Scholar
• Tse RV, Guha C, Dawson LA. 2008. Conformal radiotherapy for hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 67:113–123.
   PubMed Web of Science ®Google Scholar
• Urick ME, Chung EJ, Shield WP 3rd, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE. 2011. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clinical Cancer Research 17:5038–5047.
   PubMed Web of Science ®Google Scholar
• Wang M, Morsbach F, Sander D, Gheorghiu L, Nanda A, Benes C, Kriegs M, Krause M, Dikomey E, Baumann M, Dahm-Daphi J, Settleman J, Willers H. 2011. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Research 71:6261–6269.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 7:3129–3140.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Wysocki PJ. 2010. Targeted therapy of hepatocellular cancer. Expert Opinion on Investigational Drugs 19:265–274.
   PubMed Web of Science ®Google Scholar